Search Results 541-550 of 9284 for Mediate
About this study. This study aims to create a registry for primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic ...
Mocetinostat is an orally administered histone deacetylase (HDAC) inhibitor. Azacitidine is a hypomethylating agent (HMA) used to treat MDS. In this study, ...
About this study. The purpose of this study is to determine if elevations in oxidative stress, as measured by oxidation-reduction potential (ORP), ...
The purpose of this study is to evaouate how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) ...
Participant has history of chronic or recurrent (within the last year prior to leukapheresis) severe autoimmune or immune mediated disease (e.g., Crohn's ...
Participants with primary EGFR mutated disease, with a documented EGFR alteration (example, C797S) mediating resistance to previous treatment with a third ...
About this study. The purpose of this study is to obtain PK data on OTL38, following a single-dose injection of 0.025 mg/kg, in a pediatric population aged ...
The purpose of this research is to study immune cells called T cells and monocytes (types of blood cells that fight infection and can also cause autoimmune ...
STUDY BACKGROUND. Stroke is one of the most significant health problems in the United States and with an aging population.
Prior exposure to immune-mediated therapy, except for anti-PD-1 or anti-PD-L1 therapy in NSCLC patients; this includes anti-CTLA-4, anti-PD-1, anti-PD-L1 ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.